Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CLNN

Clene Inc

Mar 25 • 11:33AM ET

3.46

Dollar change -0.46
Percentage change -11.61	%

Consumer Defensive • Packaged Foods • USA • NASD

Peers: CYCN IMNM KNSA MTEM NAII PAVM RARE TERN XAIR

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.87	Insider Own	34.71%	Shs Outstand	8.09M	Perf Week	-22.31%
Market Cap	28.85M	Forward P/E	-	EPS next Y	-2.29	Insider Trans	4.34%	Shs Float	5.44M	Perf Month	-18.09%
Income	-39.40M	PEG	-	EPS next Q	-0.92	Inst Own	6.06%	Short Float	2.12%	Perf Quarter	-19.42%
Sales	0.34M	P/S	84.86	EPS this Y	41.53%	Inst Trans	-19.74%	Short Ratio	2.11	Perf Half Y	-30.70%
Book/sh	-1.09	P/B	-	EPS next Y	30.84%	ROA	-98.90%	Short Interest	0.12M	Perf Year	-59.24%
Cash/sh	1.46	P/C	2.37	EPS next 5Y	-	ROE	-1738.36%	52W Range	3.82 - 9.20	Perf YTD	-34.75%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-43.51%	ROI	-368.19%	52W High	-62.34%	Beta	0.35
Dividend TTM	-	Quick Ratio	1.56	Sales past 5Y	63.66%	Gross Margin	-401.46%	52W Low	-9.25%	ATR (14)	0.30
Dividend Ex-Date	-	Current Ratio	1.57	EPS Y/Y TTM	41.82%	Oper. Margin	-9676.32%	RSI (14)	26.45	Volatility	5.59% 6.96%
Employees	76	Debt/Eq	-	Sales Y/Y TTM	-47.71%	Profit Margin	-11520.47%	Recom	1.00	Target Price	38.60
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-2014.77%	Payout	-	Rel Volume	4.47	Prev Close	3.92
Sales Surprise	-34.20%	EPS Surprise	-64.41%	Sales Q/Q	-46.47%	Earnings	Mar 24 BMO	Avg Volume	54.54K	Price	3.46
SMA20	-19.94%	SMA50	-23.38%	SMA200	-33.34%	Trades		Volume	85,174	Change	-11.61%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-04-22	Downgrade	Oppenheimer	Outperform → Perform
Jul-18-22	Initiated	H.C. Wainwright	Buy	$16
May-02-22	Initiated	Canaccord Genuity	Buy	$10
Sep-28-21	Initiated	Oppenheimer	Outperform	$20

Today 08:30AM	Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025 (NewMediaWire) -11.61%
Mar-24-25 09:10AM	Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -5.31%
08:00AM	Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights (GlobeNewswire)
Mar-18-25 03:30PM	Q1 Virtual Investor Summit: On-Demand Presentations Now Live (ACCESS Newswire)
Mar-12-25 08:00AM	Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8 Treatment (GlobeNewswire)
08:30AM	Loading…
Mar-06-25 08:30AM	Clene to Present at the 37TH Annual Roth Conference (GlobeNewswire)
Feb-27-25 09:15AM	Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11 (ACCESSWIRE)
Feb-25-25 08:00AM	Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8 's Impact on NfL Reduction (GlobeNewswire)
Feb-14-25 11:29AM	Is Clene Inc. (CLNN) the Best Nanotech Penny Stock to Invest In? (Insider Monkey) +5.48%
Jan-13-25 11:18AM	IBN Coverage: Clene (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS (NewMediaWire)
Dec-30-24 09:20AM	IBN Coverage: Clene (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R) (NewMediaWire)
Dec-19-24 02:44PM	IBN Coverage: Clene (NASDAQ: CLNN) Secures $10M Debt Facility to Advance Neurodegenerative Disease Treatments (NewMediaWire)
08:00AM	Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan (GlobeNewswire)
Dec-11-24 11:15AM	IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval Pathway (NewMediaWire)
Dec-10-24 08:30AM	FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8 Biomarker Data in ALS (GlobeNewswire)
07:11AM	Loading…
Nov-15-24 07:11AM	Clene price target lowered to $83 from $86 at Canaccord (TipRanks)
Nov-13-24 08:00AM	Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights (GlobeNewswire) -9.06%
Oct-25-24 12:09PM	IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership (NewMediaWire)
Oct-21-24 01:13PM	IBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor Conferences (NewMediaWire)
Oct-11-24 02:55PM	IBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private Placements (NewMediaWire)
Oct-09-24 01:31PM	IBN Coverage: Clene (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences (NewMediaWire) +14.04%
08:00AM	Clene to Present at Upcoming October Conferences (GlobeNewswire)
Oct-03-24 10:46AM	IBN Coverage: Clene (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M (NewMediaWire)
Oct-02-24 07:21AM	IBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements (NewMediaWire) +6.30%
Oct-01-24 04:00PM	Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility (GlobeNewswire)
Sep-30-24 08:30AM	Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules (GlobeNewswire)
Sep-26-24 11:44AM	IBN Coverage: Clene (NASDAQ: CLNN) to Discuss CNM-Au8(R) Data FDA Leadership (NewMediaWire)
Sep-16-24 08:30AM	Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data (GlobeNewswire) -17.06%
Sep-04-24 11:27AM	IBN Coverage: Clene (NASDAQ: CLNN) Management to Present at H.C. Wainwright Investment Conference (NewMediaWire) +12.50%
Sep-03-24 10:38AM	IBN Coverage: Clene (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases (NewMediaWire) +12.33%
08:00AM	Loading…
08:00AM	Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-29-24 12:13PM	IBN Coverage: Clene (NASDAQ: CLNN) CEO Discusses CNM-Au8(R) Trial Results on BioMedWire Podcast (NewMediaWire)
Aug-23-24 10:17AM	IBN Coverage: Clene's (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers, Long-term Survival in ALS Trials (NewMediaWire)
Aug-13-24 12:47PM	IBN Coverage: Clene (NASDAQ: CLNN) Makes Strides in Developing CNM-Au8(R) to Address Neurodegenerative Conditions (NewMediaWire)
Aug-12-24 08:00AM	IBN Coverage: Clene (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode (NewMediaWire)
Aug-09-24 09:00AM	IBN Coverage: Clene (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates (NewMediaWire) +14.74%
Aug-08-24 08:00AM	IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc. (GlobeNewswire)
Aug-07-24 08:23AM	Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights (GlobeNewswire) -23.47%
Aug-06-24 08:00AM	Clene Announces New CNM-Au8 Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS (GlobeNewswire) +47.00%
Aug-05-24 08:00AM	Clene to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase (GlobeNewswire) -7.62%
Jul-17-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Jul-12-24 10:34AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Jul-11-24 09:00AM	Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8 in ALS (GlobeNewswire) -9.61%
Jul-09-24 08:00AM	Clene Announces 1-for-20 Reverse Stock Split (GlobeNewswire) -21.54%
Jun-24-24 08:00AM	Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
Jun-21-24 07:09AM	Clene Presents Preliminary Data for CNM-Au8 as a Potential Treatment for Rett Syndrome (GlobeNewswire)
Jun-18-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting (GlobeNewswire)
Jun-12-24 07:46AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire)
Jun-05-24 08:00AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
May-28-24 07:30AM	Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8 in ALS (ACT-EAP) (GlobeNewswire)
May-14-24 08:00AM	Clene to Present at Upcoming May Conferences (GlobeNewswire)
May-10-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
May-08-24 12:54PM	CLNN Stock Earnings: Clene Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:55AM	Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights (GlobeNewswire)
06:00AM	3 Speculative Penny Stocks Offering High-Upside Potential for Under a Buck (InvestorPlace)
May-01-24 08:30AM	IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington (GlobeNewswire)
Apr-16-24 04:01PM	Evidence for Clene's CNM-Au8 as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting (GlobeNewswire) -6.46% +9.55%
Mar-19-24 08:30AM	IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington (GlobeNewswire)
Mar-15-24 08:00AM	Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8® (GlobeNewswire)
Mar-13-24 09:30AM	Clene Inc. (CLNN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights (GlobeNewswire)
Mar-07-24 08:00AM	Clene to Present at the 36th Annual ROTH Conference (GlobeNewswire)
Feb-29-24 08:00AM	Clene Presents Clinical Results of CNM-Au8 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024 (GlobeNewswire) -7.28%
Feb-22-24 08:00AM	Clene Reports Significant Survival Benefit With CNM-Au8 Treatment in ALS EAP Compassionate Use Programs (GlobeNewswire)
Feb-05-24 02:30PM	Clene Inc. announces positive results from CNM-Au8 results from MS trial (News Direct) -6.18%
Jan-24-24 08:30AM	Clene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatment (NewMediaWire) +9.11%
Jan-10-24 09:00AM	Clene Announces Significant Positive Results from LTE VISIONARY-MS Trial (NewMediaWire)
Jan-08-24 07:00AM	Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8 Treatment in VISIONARY-MS Trial Long-Term Open Label Extension (GlobeNewswire) +22.07%
Jan-03-24 04:25PM	Clene's Phase 2 REPAIR-PD and REPAIR-MD Trials Support Advancement to Phase 3 (NewMediaWire)
Dec-22-23 03:00PM	Clene Announces New Data from HEALEY ALS Platform Trial (NewMediaWire) -7.94%
Dec-21-23 07:46AM	FDA unconvinced by Clene's request for ALS therapy's accelerated approval tag (FierceBiotech.com) -38.83%
07:00AM	Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8 Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension (GlobeNewswire)
07:00AM	Clene Provides Update on ALS Clinical Development Meeting With FDA (GlobeNewswire)
Dec-19-23 09:00AM	How Clene CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders (NewMediaWire) +9.35%
Dec-15-23 03:00PM	Clene Lead Drug Candidate Featured in Peer-Reviewed Publication (NewMediaWire)
Dec-14-23 08:36AM	Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases (GlobeNewswire)
Dec-12-23 08:30AM	Clene's Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patients (NewMediaWire) -6.45%
Dec-08-23 02:19PM	Nobel Prize in Chemistry's Spotlight on Nanotechnology Shines Light on Clene Efforts to Develop Catalytically Active Nanoparticles (NewMediaWire)
Nov-23-23 09:00AM	Clene Capitalizing on Promising Chemical and Therapeutic Properties of Nanocrystals (NewMediaWire)
Nov-14-23 08:30AM	Clene Among Grant Awardees Selected to Advance Scientific Research on ALS (NewMediaWire) -6.78%
Nov-09-23 09:00AM	Clene Announces Q3 2023 Financial Results, Operating Highlights (NewMediaWire)
Nov-07-23 08:57AM	Clene Inc (CLNN) Reports Q3 2023 Financial Results: Significant Survival Benefits and $45. ... (GuruFocus.com) +8.02%
08:00AM	Clene Reports Third Quarter 2023 Financial Results and Operating Highlights (GlobeNewswire)
Oct-31-23 08:30AM	Clene Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis (NewMediaWire)
Oct-26-23 08:30AM	Clene Announces Four-Year Grant to Support Expanded Access Protocol for CNM-Au8 From NINDS (NewMediaWire)
Oct-19-23 08:30AM	Clene 'Innovates' Investigational Drug With Patented Nanotechnology (NewMediaWire)
Oct-17-23 08:30AM	Clene Applies Patented Nanotechnology to Development of CNM-Au8(R), Its Investigational Drug for ALS (NewMediaWire) -5.77%
Oct-11-23 09:00AM	Clene CEO Featured in Latest Episode of The Bell2Bell Podcast (NewMediaWire)
Oct-06-23 02:15PM	Clene Announces $45.1M NINDS Grant (NewMediaWire)
Oct-05-23 10:00AM	National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8 Study in ALS (GlobeNewswire) +9.98%
Sep-29-23 03:00PM	Clene Investigational Drug Focus of Study Published in Peer-Reviewed Journal (NewMediaWire)
08:30AM	Clene Inc. Is 'One to Watch' (NewMediaWire)
Sep-28-23 08:00AM	Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action (GlobeNewswire) -5.30%
Sep-27-23 09:00AM	Clene Releases Significant Long-Term Survival Improvement Data from ALS Trial (NewMediaWire)
Sep-25-23 04:00PM	Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference (GlobeNewswire) +13.15%

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
General Resonance LLC	10% Owner	Mar 19 '25	Sale	4.40	1,400	6,160	710,852	Mar 19 06:47 PM
General Resonance LLC	10% Owner	Mar 18 '25	Sale	4.45	1,333	5,932	712,252	Mar 19 06:47 PM
MATLIN DAVID J	Director	Sep 30 '24	Buy	4.75	92,307	438,458	444,491	Oct 02 12:58 PM
Mortenson Mark	Chief Science Officer	Sep 30 '24	Buy	4.75	20,512	97,432	28,949	Oct 01 04:17 PM
Etherington Robert Dee	Chief Executive Officer	Sep 30 '24	Buy	4.75	10,000	47,500	40,149	Oct 01 04:17 PM
Etherington Robert Dee	Chief Executive Officer	Jul 29 '24	Option Exercise	3.00	27,320	81,960	30,149	Jul 30 09:03 AM
General Resonance LLC	10% Owner	Apr 30 '24	Sale	0.42	13,000	5,416	15,326,712	May 08 12:16 PM
General Resonance LLC	10% Owner	May 01 '24	Sale	0.40	13,000	5,148	15,313,712	May 08 12:16 PM
General Resonance LLC	10% Owner	Apr 24 '24	Sale	0.33	10,000	3,278	15,349,712	May 01 05:13 PM
General Resonance LLC	10% Owner	Apr 09 '24	Sale	0.39	22,500	8,674	15,428,212	Apr 16 09:38 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLNN

Clene Inc

Upgrade your FINVIZ experience